Meet Natasha, a 28-year-old Australian who's cracked the code to financial freedom. With $310,000 in shares and a seven-figure net worth, she shares the powerful yet simple wealth-building strategies that transformed her financial future.
Australian pharmaceutical giant Mayne Pharma faces investor backlash as its controversial US licensing agreement continues to dominate trading, creating clear winners and losers on the ASX.
Discover how bond laddering and duration management can help Australian investors navigate interest rate uncertainty and safeguard their portfolios against market turbulence.